Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Global Healthcare Today.
Press releases published on July 29, 2025
UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025
GlobeNewswire
·
July 29, 2025
Conference Call and Webcast Scheduled for Thursday, August 7th, 2025, at 10:00 AM ET PRINCETON, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions …
Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma
GlobeNewswire
·
July 29, 2025
SAN DIEGO, July 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic …
Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results
GlobeNewswire
·
July 29, 2025
BOSTON, July 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by …
Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer’s Disease
GlobeNewswire
·
July 29, 2025
- Pioneering approach to halting the chronic neuroinflammation responsible for neurodegeneration - Trial to assess safety, PK and detect early signs of efficacy - Initial data expected in mid-2026 SACRAMENTO, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- …
Izotropic’s IzoView Breast CT Device Stands Distinct vs Existing Breast Imaging Technologies
GlobeNewswire
·
July 29, 2025
- IzoView positioned to disrupt high-growth breast imaging markets with target device price of USD $500K - IzoView to launch into projected fastest-growing imaging category with potential to displace well-established technologies - Differentiated from …
Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301
GlobeNewswire
·
July 29, 2025
KANSAS CITY, Kan., July 29, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation …
Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream
GlobeNewswire
·
July 29, 2025
A first-of-its-kind solution for women’s arousal in a proprietary topical formulation demonstrated to work where women need it most Targeted to be available by prescription in the fourth quarter of 2025 Collaboration leverages Rosy Wellness’ extensive …
ProPhase Labs Announces Special Meeting of Shareholders and Filing of Preliminary Proxy Statement
GlobeNewswire
·
July 29, 2025
Proxy Sets Company on a Path to Attract the Optimal Crypto Treasury Strategy Increase in Authorized Shares to 1 Billion Would Position the Company to Attract Industry-Leading Market Participants and High-Value Crypto Treasury Transactions UNIONDALE, NY, …
Exagen Inc. Reports Strong Q2 2025 Results
GlobeNewswire
·
July 29, 2025
CARLSBAD, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2025, and recent corporate updates. Three Months Ended …
Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer
GlobeNewswire
·
July 29, 2025
SYDNEY, AUSTRALIA, July 29, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an upcoming poster presentation for the …
Vivex Biologics, Inc. Completes Subject Enrollment for its ASCEND Trial Evaluating VIA Disc NP™ for Symptomatic Disc Degeneration
GlobeNewswire
·
July 29, 2025
MIAMI, July 29, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, today announced that it has completed subject enrollment in its ASCEND clinical trial evaluating VIA Disc NP for symptomatic …
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
GlobeNewswire
·
July 29, 2025
Presentation to highlight the Company’s proprietary protein-misfolding platform, EpiSelectTM, used to develop PMN310 Posters highlighting PRECISE-AD, the Company’s Phase 1b clinical trial design and optimization of biomarkers in AD Progress with trial …
Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease
GlobeNewswire
·
July 29, 2025
- Zervimesine’s impact on debilitating DLB behavioral symptoms highlighted in podium presentation - - Plasma p-tau217 levels can identify Alzheimer’s patients most likely to benefit from zervimesine treatment - - Plasma and CSF biomarkers support …
BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents
GlobeNewswire
·
July 29, 2025
TILsRx platform designed to overcome immune suppression and T cell exhaustion to activate tumor-infiltrating lymphocytes (TILs) Multivalent technology enables simultaneous engagement of multiple cancer-associated and immune pathway targets A preferred …
Radiopharm Theranostics reports Fiscal Year 2025 Financial Results and Business Update
GlobeNewswire
·
July 29, 2025
On track to complete enrollment of first two cohorts of RAD204 following positive recommendation from DSMC to escalate dose to 60mCi of Lu177 On track to complete enrollment of the first cohort of Phase 1 ‘HEAT’ trial of RAD202 for treatment of advanced …
Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution
GlobeNewswire
·
July 29, 2025
– ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth – – ARCALYST 2025 expected net product revenue increased to $625 - $640 million – – KPL-387 Phase 2/3 clinical trial in recurrent pericarditis …
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
GlobeNewswire
·
July 29, 2025
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on …
Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance
GlobeNewswire
·
July 29, 2025
Revenue of $182 million, year-over-year increase of 15% as reported and 17% organic non-COVID growth Orders grew sequentially and greater than 20% year-over-year Increasing revenue guidance to range of $715 to $735 million, which represents 12.5% -15.5% …
Quipt Home Medical Corp. to Announce Fiscal Third Quarter 2025 Financial Results on August 11, 2025
GlobeNewswire
·
July 29, 2025
CINCINNATI, July 29, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, will announce its fiscal Third quarter 2025 financial …
QuasarMD Unveils Advanced Full-Body Light Therapy Mat to Support Aging Wellness
GlobeNewswire
·
July 29, 2025
CHINO, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- QuasarMD LLC, a leader in light-based wellness technologies, announces the launch of its Full-Body Light Therapy Mat, a clinically validated, non-invasive solution designed to address the evolving wellness …